FCS

Showing 2 posts of 2 posts found.

47028496254_21a33b62df_b

NICE rules against the use of Akcea’s Waylivra in the NHS

January 3, 2020
Medical Communications Akcea, European Commission, FCS, NHS, NICE

NICE has not recommended Akcea’s drug Waylivra (volanesorsen) to be used for the treatment of Familial Chylomicronaemia Syndrome (FCS) in …

shutterstock_38078521

Akcea and Ionis’ Waylivra nets CHMP approval in ultra-rare familial chylomicronaemia syndrome

March 5, 2019
Manufacturing and Production, Sales and Marketing Akcea, FCS, Ionis, familial chylomicronemia syndrome, pharma, rare disease

Akcea Therapeutics and Ionis Pharmaceuticals have announced that their investigational therapy Waylivra (volanesorsen) has been recommended by the EMA’s Committee …

Latest content